Companies › VM Discovery
1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout May 2031.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| VMD-102 PKC epsilon (PKCε) kinase inhibitor | PRKCE | Phase 1 | Hepatocellular Carcinoma (HCC) | May 2031 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07636785 | VMD-102 | Phase 1 | Hepatocellular Carcinoma (HCC) | Oncology | May 2031 |
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.